TNDM
Tandem Diabetes Care, Inc.
Nasdaq · usd
Tandem Diabetes Care, Inc. (TNDM) trades at $20.07 (+14.62%) as of 7:39:46 PM EST on Nov 13, 2026, +21.49% over the past month. Market cap is $1.4B, with 7.6 days to cover in short interest.
Stock performance
How Tandem Diabetes Care, Inc. (TNDM) stock has performed from one day to one year, with its 52-week range.
- 1D
- +14.62%
- 1W
- +18.69%
- 1M
- +21.49%
- YTD
- -8.69%
- 1Y
- +9.43%
- 52-wk range
- $12.26 – $29.65
Key statistics
Today's trading snapshot for TNDM: day range, open, previous close, volume and market cap.
- Day range
- $18.53 – $20.26
- Open
- $19.00
- Prev close
- $17.51
- Volume
- 4.4M
- Market cap
- $1.4B
- Shares out
- 69.79M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Tandem Diabetes Care, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 1.30
- P/B
- 10.37
- P/FCF
- —
- ROE
- -36.4%
- ROA
- -4.3%
- Debt/Equity
- 4.47
- Div yield
- 0.00%
As of Nov 13, 2026
8-K filings
Material corporate events Tandem Diabetes Care, Inc. has disclosed to the SEC on Form 8-K.
- Product or service launchNov 13, 2026
A new Tandem Mobi tubeless cartridge and infusion set converts the current Tandem Mobi pump into a tubeless device that can help simplify diabetes management with less frequent site changes, while offering the life-changing benefits of Control-IQ+ advanced hybrid closed-loop technology. Full commercial launch of the new tubeless cartridge and infusion set for Tandem Mobi is planned for the first half of 2027 in the United States.
- Quarterly earningsNov 5, 2026
On November 5, 2026, Tandem Diabetes Care, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.
- Charter amendmentMay 21, 2026
On May 20, 2026, at the 2026 Annual Meeting of Stockholders, the Company's stockholders approved amendments to the Company's Amended and Restated Certificate of Incorporation to: (i) provide for removal of directors with or without cause, as required by Section 141(k) of the Delaware General Corporation Law (DGCL); and (ii) among other things, (x) limit the liability of officers of the Company to the maximum extent permitted by law as permitted pursuant to Section 102(b)(7) of the DGCL and (y) implement certain other changes based on updates to the DGCL.
- Executive officer departureMay 15, 2026
Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the "Company"), was notified that his employment with the Company is being terminated without cause. Mr. Novara's last day of employment with the Company is scheduled to be May 18, 2026.
- Debt issuanceFeb 27, 2026
On February 27, 2026, Tandem Diabetes Care, Inc. (the "Company") completed its previously announced private offering (the "Offering") of $300.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "Notes"), including the exercise in full of the initial purchasers' option to purchase up to an additional $35.0 million principal amount of Notes. The Notes were issued in accordance with an indenture, dated February 27, 2026 (the "Indenture"), between the Company and U.S. Bank Trust Company, National Association, as trustee.
Dividend history and stock splits
Tandem Diabetes Care, Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-10Oct 10, 2017
TNDM short interest
How heavily TNDM is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 7.6
- Short interest
- 16.17M
- Avg volume
- 2.12M
As of · reported to FINRA twice monthly.
TNDM news
The latest news and headlines about Tandem Diabetes Care, Inc. (TNDM).
- Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to SayneutralZacks Investment Research· Nov 5, 2026
- Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue EstimatesnegativeZacks Investment Research· Nov 5, 2026
- Is it the Right Time to Hold TNDM Stock in Your Portfolio?neutralZacks Investment Research· Oct 9, 2026
- Reasons to Retain Tandem Diabetes Stock in Your Portfolio NowneutralZacks Investment Research· Sep 9, 2026
- Aging Population Drives Healthcare Growth: Stocks to WatchpositiveZacks Investment Research· Aug 31, 2026
Frequently asked questions
What is the Tandem Diabetes Care, Inc. (TNDM) stock price today?
Tandem Diabetes Care, Inc. (TNDM) is trading at $20.07 (+14.62% on the day) as of 7:39:46 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Tandem Diabetes Care, Inc.?
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device.
What is the short interest in TNDM?
As of Oct 30, 2026, TNDM has 16.17M shares short and 7.6 days to cover.
What exchange is TNDM listed on?
Tandem Diabetes Care, Inc. (TNDM) trades on Nasdaq in USD, in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry.
Build with AI
Build an analysis of TNDM with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a TNDM analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.